Stocktoria
Pelthos Therapeutics Inc. PTHS
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-16
Pelthos Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating margin | -193.1% | — | — | — |
| Net margin | -257.9% | — | — | — |
| FCF margin | -135.1% | — | — | — |
| Return on assets | -33.2% | -581.1% | -7657.1% | -4464.2% |
| Return on equity | -111.4% | 293.1% | 114.5% | 66.3% |
| Current ratio | 2.05 | 0.34 | 0.01 | 0.01 |
Source: SEC EDGAR filings · CIK 0001919246 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.